USPTO serial 79195512
RIVOPHARM
Reviewed by CopyMark Law Group
Reg. 5234473Status 709
- Filing date
- Status date
- Registration date
- Jul 4, 2017
- Examiner
- MURRAY, DAVID T
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with RIVOPHARM?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Jeffrey B. Sladkus
Jeffrey B. Sladkus The Sladkus Law Group1827 Powers Ferry RoadBuilding 6, Suite 200Atlanta, GA 30339Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations, both prescription and over-the-counter, namely, pharmaceutical preparations for peptic ulcer and gastrooesophageal reflux disease (GORD), propulsives, intestinal anti-infectives, intestinal anti-inflammatory agents, oral pharmaceutical preparations for lowering blood glucose, Vitamin A and D, mixed vitamin preparations consisting of vitamins A and D, vitamin and mineral preparations for medical use, vitamin C in the nature of ascorbic acid mixed vitamin preparations consisting partially of Vitamin C, calcium supplements, mineral supplements, anti-thrombotic agents, intravenous solutions, cardiac glycosides, class I and class III anti-arrhythmics, pharmaceutical preparations for cardiac stimulation excluding cardiac glycosides, Vasodilators used in the treatment of cardiac diseases, anti-adrenergic agents, pharmaceutical preparations for acting on arteriolar smooth muscle, Beta blocking agents, Selective calcium channel blockers, pharmaceutical preparations in the nature of Angiotensin Converting Enzyme inhibitors, pharmaceutical preparations in the nature of Angiotensin Converting Enzyme inhibitors combined with other pharmaceutical preparations, anti-fungals for systemic use, anti-infectives and antiseptics, excluding those combined with corticosteroids, oxytocics, plain corticosteroids for systemic use, thyroid preparations, anti-thyroid preparations, tetracyclines preparations, macrolides, lincosamides and streptogramins, aminoglycoside antibacterials, quinolone antibacterials, antimycotics for systemic use, direct acting antivirals, immune sera, bacterial vaccines, alkylating agents, anti-metabolites, plant alkaloids, cytotoxic antibiotics, hormone antagonists and related agents, namely, anti-estrogens, anti-androgens and enzyme inhibitors, immunosuppressive agents, antiinflammatory and antirheumatic preparations, non-steroids in the nature of butylpyrazolidines, acetic acid derivatives, oxicams, propionic acid derivatives, fenamates, Coxibs, muscle relaxants, peripherally acting agents in the nature of curare alkaloids and choline derivatives, antigout preparations, analgesics and antipyretics preparations, anti-migraine preparations, anti-epileptic preparations, anti-cholinergic agents, dopaminergic agents, anti-psychotics, anxiolytics, hypnotics and sedatives, antidepressants, parasympathomimetics, agents for use against amoebiasis and other protozoal diseases, anti-malarial preparation, adrenergics, inhalant anesthetics, adrenergics for systemic use, antihistamines for systemic use, diuretic agents | SECTION 71 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jul 30, 2026 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Nov 17, 2024 | INNT | TOTAL INVALIDATION PROCESSED BY THE IB | — |
| Sep 24, 2024 | INTS | TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB | — |
| Sep 24, 2024 | INPC | INVALIDATION PROCESSED | — |
| Sep 20, 2024 | INTR | TOTAL INVALIDATION OF REG EXT PROTECTION CREATED | — |
| Jan 19, 2024 | C71T | CANCELLED SECTION 71 | — |
| Jul 4, 2022 | REM3 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED | — |
| Nov 3, 2017 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Oct 13, 2017 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Oct 10, 2017 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Oct 10, 2017 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Oct 4, 2017 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Jul 4, 2017 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Apr 18, 2017 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Apr 18, 2017 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Mar 29, 2017 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Mar 29, 2017 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Mar 29, 2017 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Mar 10, 2017 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Mar 6, 2017 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Mar 6, 2017 | DMCC | DATA MODIFICATION COMPLETED | — |
| Mar 3, 2017 | ALIE | ASSIGNED TO LIE | — |
| Mar 2, 2017 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Mar 2, 2017 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Mar 2, 2017 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 1, 2017 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 1, 2017 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Dec 9, 2016 | RFNT | REFUSAL PROCESSED BY IB | — |
| Nov 15, 2016 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Nov 15, 2016 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Nov 11, 2016 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Nov 9, 2016 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Nov 8, 2016 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 7, 2016 | DOCK | ASSIGNED TO EXAMINER | — |
| Nov 7, 2016 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Nov 3, 2016 | SDRC | SN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB | — |